A Routine Research Study Reveals a Rare Genetic Risk in Two Brothers

A decision that initially seemed almost insignificant has given one West Yorkshire family the chance to identify a serious inherited health risk before either of two young brothers developed symptoms.

Jessica Barker-Roe, 32, enrolled her baby son Revan in the Generation Study while she was in hospital during pregnancy. She described the decision as something she made largely because she was bored during a long hospital stay. At the time, she had no reason to believe the test would uncover anything unusual.

Months later, the study revealed that Revan carried a genetic change associated with adrenoleukodystrophy, or ALD, a rare inherited condition that can affect the nervous system and adrenal glands.

The discovery also led doctors to test his older brother, Thorin, who is four. He was found to have the same genetic change.

For the family, the result has created a very different future from the one they might otherwise have faced. Instead of waiting for symptoms to appear, Revan and Thorin can now be monitored by specialists who can act if signs of disease emerge.

An unexpected discovery

The Generation Study is a major research programme examining whether whole genome sequencing could eventually become part of routine newborn screening in England.

Unlike traditional screening methods, whole genome sequencing examines a person's genetic code in much greater detail. The Generation Study is looking for genetic changes associated with more than 200 rare conditions, including disorders that may not cause obvious symptoms during infancy.

Revan was given the test using a heel prick sample after his mother agreed to participate. The result indicated that he had a genetic change linked to ALD.

The finding was particularly important because ALD can be difficult to recognise in its early stages. Symptoms may not be obvious at first, and families may only discover that something is wrong after a child begins experiencing developmental, neurological or other health problems.

In this case, the early result allowed doctors to investigate the family history and test Revan's brother.

Thorin was approaching an age at which some forms of ALD can begin to cause serious neurological problems, making the discovery especially significant.

What is ALD?

Adrenoleukodystrophy is a rare inherited disorder that can affect several parts of the body.

According to information from Great Ormond Street Hospital for Children, ALD can affect the adrenal glands, which are responsible for producing important hormones. It can also affect the nerves of the spinal cord and, in some cases, the white matter of the brain.

The condition can vary considerably between individuals. Some people experience adrenal problems, while others develop neurological symptoms. A particularly serious form, cerebral ALD, can affect the brain.

Importantly, carrying a genetic change associated with ALD does not necessarily mean that a child will develop every form of the condition.

However, knowing that a child is at risk can allow medical teams to carry out regular monitoring and respond quickly if concerning changes occur.

For Revan and Thorin, this means ongoing medical surveillance rather than waiting for a problem to become obvious.

Why early diagnosis matters

The family has been told that the boys will undergo regular MRI scans, reportedly every six months until around the age of 12, alongside blood tests to monitor adrenal function.

The reason for this close monitoring is that timing can be crucial when managing ALD.

Once certain neurological symptoms become established, treatment options can become considerably more limited. Detecting changes before significant symptoms develop may give specialists an opportunity to intervene at a stage when treatment has a better chance of preventing or reducing serious complications.

For the Barker-Roe family, that possibility has transformed what could have been a frightening diagnosis into a situation where doctors have a plan for the future.

Jessica said she felt fortunate that the study was available at precisely the time her family encountered it.

Had she not been in hospital, she believes she may never have heard about the research programme. Without the test, the family might only have discovered the condition after one of the children became unwell.

That possibility highlights one of the central questions behind the Generation Study: whether genetic screening can identify serious conditions before families have any reason to suspect that something is wrong.

A wider experiment in newborn screening

The Barker-Roe family's experience forms part of a much larger research project.

The Generation Study was launched by Genomics England in partnership with NHS England. It is examining whether whole genome sequencing could be used alongside existing newborn screening to identify children who are at risk of rare genetic disorders.

The project has been offered through more than 70 hospitals in England. According to information provided in the report, more than 85,000 families had joined the study and more than 200 results classed as "condition suspected" had been returned to the NHS for further testing.

The existing newborn heel prick programme already checks babies for a number of rare but serious conditions. The Generation Study is designed to explore whether genomic testing could identify many additional disorders, particularly those where symptoms may not appear until months or years later.

Researchers hope that earlier identification could reduce diagnostic delays and allow children to receive specialist care sooner.

The questions surrounding genetic screening

While early diagnosis can provide enormous benefits, programmes involving genetic testing also raise important questions.

Parents may have to consider what they want to know about their child's future health and how they would feel about receiving information about a condition that may never actually develop.

There are also questions about how genetic results should be interpreted, confirmed and communicated. A research result is not necessarily the same as a final medical diagnosis, which is why follow-up testing and specialist assessment are essential.

The Generation Study is intended to help researchers understand these issues as well as the potential medical benefits.

Professor Rich Scott, chief executive of Genomics England, said the experience of the Barker-Roe family demonstrated the type of evidence the study is intended to generate. Earlier identification can potentially allow earlier care while also improving understanding of rare diseases.

NHS England has similarly highlighted the opportunity to connect genomic research with routine healthcare.

A different future for one family

For Jessica and Dominic Barker-Roe, the significance of the study is deeply personal.

Their sons now have medical teams watching for potential changes rather than doctors having to start investigating only after symptoms appear.

That does not remove all uncertainty. A genetic risk is not the same thing as a guarantee that a serious illness will develop. The family will still face years of monitoring and medical appointments.

But the difference is that they have information and a plan.

Their story also demonstrates how developments in genomic medicine could change the way rare diseases are detected. Conditions that once remained hidden until a child became visibly unwell may increasingly be identified much earlier.

For the Barker-Roe brothers, a simple decision to participate in a research study has provided an opportunity for early specialist care. For researchers, their experience offers another piece of evidence in the much bigger debate over whether genomic screening should eventually be offered routinely to newborn babies across the NHS.

Source: The Independent on 21 August 2026. including information attributed to Genomics England, NHS England, Great Ormond Street Hospital for Children and the Barker-Roe family.

Disclaimer: This article is for general information only and is not medical advice. Genetic conditions can affect people differently, and a genetic finding does not necessarily mean that a person will develop a particular disease. Anyone with concerns about genetic testing, ALD or a child's health should speak with an appropriately qualified healthcare professional.